



# CNIV 2017

## « 2<sup>ÈME</sup> CONGRÈS NATIONAL D'IMAGERIE DU VIVANT »

8 - 9 NOVEMBRE 2017 – INSTITUT PASTEUR (PARIS)

**medicen** | innovation  
PARIS REGION for  
health

APPEL À MANIFESTATION D'INTÉRÊT  
OFFRE DE SERVICES



*ONCODESIGN – PHARM'IMAGE*



# 1. PRÉSENTATION DU PRESTATAIRE



## PHARM'IMAGE: One place for whole pharmaco-imaging



### Pharm'Image, an Industrial- Academic Economic Association dedicated to pharmaco-imaging

- Multimodality preclinical and clinical imaging capabilities on 1 km<sup>2</sup> in Dijon
- Includes cyclotron for research and GMP production purposes
- Clinical center accredited for phase 0/1 clinical trials
- Multiple academic and biotech partners with specializations in the area
- Complete value chain of PET tracer development



# ▶ 1. PRÉSENTATION DU PRESTATAIRE



## PHARM'IMAGE: A network of expertise



### Pharm'Image, a collaborative network leading the scientific and economic attractiveness

- 12 M€ have been invested in dedicated buildings and platform equipment
- Over 50 M€ investment in multiple research projects focusing on pharmaco-imaging from chemistry to clinical trials
- A scientific community of more than 200 people have been associated with Pharm'Image projects
- Pharm'Image is part of regional hospital-university cluster to promote scientific excellence and new international projects
- Attractiveness of the research cluster for innovative companies (MR Solution, Cyclopharma, Ipsen, Guerbet, Diaclone...)
- High scientific visibility with more than 60 publications in the last 5 years and strong presence in congress




Pharm'Image community presented 7 oral communications and 4 posters at the European Association of Nuclear Medicine Meeting (October 2016 - Barcelona)

## 2. L'OFFRE DE SERVICES



### BIODISTRIBUTION STUDY: *From radiochemistry to nuclear imaging*



#### Bioconjugation



- Bioconjugation method development
- Evaluation of biological activity
- Production of bioconjugated molecule

#### Radio labeling

#### In vitro cell amplification

#### In vivo tumor growth

#### Biodistribution



#### Chemistry technical work

#### Biology technical work

#### Preclinical study


#### Data analysis/reporting



## 2. L'OFFRE DE SERVICES



### FLOWCHART OF A PET RADIOTRACER DEVELOPMENT



## 2. L'OFFRE DE SERVICES



### MORPHOLOGICAL MRI: Immuno-checkpoint activity evaluation




- Tumor microenvironment influences immune response: MBT-2 bladder, SC vs OT model

#### 1 SC injection of MBT-2 cells


Model				CTLA-4		PD-1	
Name	Site	Type	Strain	n	T/C (median)	n	T/C (median)
MBT-2*	OT	Bladder	C3H	1	260	3	149
MBT-2	SC	Bladder	C3H	1	83	3	73

\* Survival



n: number of study used to calculate T/C values



#### 2 OT injection of MBT-2 cells



OT injection with MBT-2 tumor cells  
Morphological MRI at D21





## 2. L'OFFRE DE SERVICES




### COMBINING MORPHOLOGICAL AND NUCLEAR IMAGING



- **IMAPPI® Program: Development of a PET/MRI preclinical prototype**



Tumor PET-MRI  
(<sup>64</sup>Cu-Fab)



Cardiac PET-MRI  
(<sup>18</sup>F-FDG)

## ▷ 3. CONTACT



**medicen**  
PARIS REGION



**Thank you !**

[www.oncodesign.com](http://www.oncodesign.com)



[www.pharmimage.eu](http://www.pharmimage.eu)

Tel: +33 (0)3 80 78 82 60 - Fax: +33 (0)3 80 78 82 61  
20, rue Jean Mazen - BP27627 - 21076 Dijon Cedex - France

[cberthet@oncodesign.com](mailto:cberthet@oncodesign.com) / [contact@pharmimage.fr](mailto:contact@pharmimage.fr)

